India's Wockhardt Launches Drug in US Market

by VR Sreeraman on  June 21, 2007 at 5:48 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

India's Wockhardt Launches Drug in US Market
Indian pharma major Wockhardt Wednesday announced the launch of its antibiotic tablets Cefprozil in the US after receiving approval from the US Food and Drug Administration (US FDA).

Cefprozil, a Cephalosporin class of antibiotics, is used in the treatment of respiratory tract and skin infections.

"Several of our products have seen a dramatic increase in the market share in the US over the last six months. Cephalosporins have been an important product in our portfolio and Cefprozil will be a good addition to this range with a market potential of around $51 million," Wockhardt chairman Habil Khorakiwala said in a statement.

The Cefprozil tablets, developed in-house, are manufactured at Wockhardt's US FDA certified formulation plant at Waluj in Maharashtra.

The $650 million firm has a market capitalisation of over $1 billion and has major presence in the markets of the US, Britain, Ireland, Germany and France. It employs over 7,000 professionals both in India and abroad.

Source: IANS
LIN/M

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive